Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 104 Lymphoid 57 Myeloid 14 Genitourinary 8 Sarcoma 3 Gynecologic 2 Classical hematology 2 Tumor-Agnostic 1 Thoracic 1 Plasma cell 1 Other solid neoplasm 1 Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Cisplatin 416 Radiotherapy 240 Radiotherapy, Intensity-Modulated 178 Cetuximab 177 Docetaxel 166 pembrolizumab 148 Carboplatin 121 Fluorouracil 113 Paclitaxel 90 Nivolumab 82 Gemcitabine 82 Radiation 72 Surveys and Questionnaires 71 Drug Therapy 70 toripalimab 68 Surgical Procedures, Operative 64 Magnetic Resonance Spectroscopy 63 Capecitabine 50 Blood Specimen Collection 50 Chemoradiotherapy 46 Biopsy 44 camrelizumab 41 durvalumab 40 Radiosurgery 40 Standard of Care 38 Erlotinib Hydrochloride 34 nimotuzumab 32 130-nm albumin-bound paclitaxel 32 tislelizumab 31 apatinib 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Mitoxantrone × Head & Neck × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡